Table 2 TLR antagonists and their associated targets and diseases
From: Negative regulatory approaches to the attenuation of Toll-like receptor signaling
Inhibitor | Target molecule | Disease |
|---|---|---|
OxPAPC | CD14, MD-2, LBP | Sepsis |
Chloroquine/hydroxychloroquine | TLR3, TLR7, TLR9 | SLE |
Imidazoquinolines | TLR3, TLR9 | Autoimmune disease |
Propidium iodide | TLR3, TLR7, TLR9 | Autoimmune disease |
EM77/110 | MyD88/TIR domain interaction blockade | Inflammatory disease |
ST2825 | Block MyD88 dimerization and interact with IRAK1 and IRAK4 | Chronic inflammatory disease |
IMO-3100 | TLR7, TLR9 | Autoimmune disease |
IRS-954 | TLR9 | Autoimmunity, SLE |
E6446 | TLR9 | Inflammatory disease |
Eritoran | TLR4 | Septic shock |
DV1179 | TLR7, TLR9 | SLE |
IPH-32XX | TLR7 | Autoimmune, cancer |
E567 | TLR2, TLR4 | Anti-viral response |
